Brief: Inozyme Pharma Highlights Inclusion Of Generalized Arterial Calcification Of Infancy In Genomics England’S Generation Study Of Rare Conditions
10/10/2023 14:01
Oct 10 (Reuters) - Inozyme Pharma Inc INZY.O :
* INOZYME PHARMA HIGHLIGHTS INCLUSION OF GENERALIZED
ARTERIAL
CALCIFICATION OF INFANCY (GACI) IN GENOMICS ENGLAND’S GENERATION
STUDY OF RARE CONDITIONS
* INOZYME PHARMA INC - GENERATION STUDY IS SCHEDULED TO
BEGIN IN
LATE 2023
Source text for Eikon: ID:nGNX1mjlBq
Further company coverage: INZY.O
((Reuters.Briefs@thomsonreuters.com))
Recent news on Inozyme Pharma
See all newsBrief: Inozyme Pharma postpones 2025 annual meeting of stockholders
U.S. RESEARCH ROUNDUP-Advansix, Cognizant, Inozyme Pharma
U.S. STOCKS ON THE MOVE-Netflix, Acadia Pharma, CoreWeave
U.S. STOCKS ON THE MOVE-Inozyme Pharma, Emerson Electric, Stanley Black & Decker
Inozyme Pharma rises over 175% on $270 million buyout deal with BioMarin